Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus

This study has been terminated.
Sponsor:
Information provided by:
Emory University
ClinicalTrials.gov Identifier:
NCT00208936
First received: September 13, 2005
Last updated: December 17, 2007
Last verified: December 2007

September 13, 2005
December 17, 2007
January 1996
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00208936 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus
Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus

This study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.

This study is designed for patients with resectable, local-regional carcinoma of the esophagus. In a pre-operative setting, chemotherapy with Taxol, Cisplatin, and 5-Fluorouracil will be administered followed by G-CSF.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Esophageal Diseases
Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
20
Not Provided
Not Provided

Inclusion Criteria:

  • Measurable disease with resectable local-regional carcinoma of the esophagus. 18 years of age or older.

Exclusion Criteria:

  • Pregnant or lactating. Non-resectable local-regional carcinoma of the esophagus.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00208936
0691-1995
Not Provided
Not Provided
Emory University
Not Provided
Principal Investigator: Michael Fanucchi, MD Emory University Winship Cancer Institute
Emory University
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP